Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: Methodological implications for immunotherapy

Medical Science Monitor

Volumn 15, Issue 12, 2009, Pages

  Hanak, Libor ^a   Slaby, Ondrej ^a,b   Lauerova, Ludmila ^b   Kren, Leos ^c   Nenutil, Rudolf ^b   Michalek, Jaroslav ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Classic HLA antigens; Immunotherapy; MTT assay; Non classic HLA antigens; Renal carcinoma

Indexed keywords

CARBOPLATIN; FLUOROURACIL; GEMCITABINE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; VINBLASTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; EXPLANT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; NEPHRECTOMY;

ADULT; AGED; CARCINOMA, RENAL CELL; CELL CULTURE TECHNIQUES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 75149173134     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. th Edition). Greene FL, Page Dl, Fleming ID et al. (eds.). Springer-Verlag, NY, USA, 2002
2. Sivori S, Parolini S, Marcenaro E et al: Triggering receptors involved in natural killer cell-mediated cytotoxicity against choriocarcinoma cell lines. Hum Immunol, 2000; 61(11): 1055-58
3. Seliger B, Schlaf G: Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol, 2007; 17(6): 444-50
4. Bukur J, Seliger B: The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin Cancer Biol, 2003; 13(5): 353-59
5. Komohara Y, Harada M, Ishihara Y et al: HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep, 2007; 18(6): 1463-68
6. Bukur J, Rebmann V, Grosse-Wilde H et al: Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res, 2003; 63(14): 4107-11
7. Favier B, LeMaoult J, Carosella ED: Functions of HLA-G in the immune system. Tissue Antigens, 2007; 69: 150-52
8. Ibrahim EC, Guerra N, Lacombe MJ et al: Tumor-specific up-regulation of the nonclassic class I HLA-G antigen expression in renal carcinoma. Cancer Res, 2001; 61(18): 6838-45
9. Malmberg KJ, Levitsky V, Norell H et al: IFN-gamma protects shortterm ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest, 2002; 110(10): 1515-23
10. Hirankarn N, Kimkong I, Mutirangura A: HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens, 2004; 64(5):588-92
11. Bukur J, Malenica B, Huber Ch et al: Altered expression of nonclassic HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum Immunol, 2003; 64(11):1081-92
12. Ibrahim EC, Allory Y, Commo F et al: Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassic human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am J Pathol, 2003; 162: 501-8
13. Satoh S, Kobayashi J, Mizoguchi J et al: Serum-free cultivation of anchorage-dependent cells on microcarrier: effective production of human macrophage colony-stimulating factor. Cytotechnology, 1991; 5(Suppl.2): S95-114
14. Hagiwara M, McNamara DB, Chen IL et al: Role of endogenous prostaglandin E2 in erythropoietin production and dome formation by human renal carcinoma cells in culture. J Clin Invest, 1984; 74(4): 1252-61
15. Heicappell R, Naito S, Ichinose Y et al: Cytostatic and cytolytic effects of human recombinant tumor necrosis factor on human renal cell carcinoma cell lines derived from a single surgical specimen. J Immunol, 1987; 138(5): 1634-40
16. Klatte D, Redmann K, Muller GW et al: Pretherapeutic testing of sensitivity to cytostatic drugs in primary cultures of selected urologic tumors. Z Urol Nephrol, 1986; 79(8): 441-47
17. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted in the different organs of nude mice. Cancer Res, 1986; 46: 4109
18. Liu CJ, Wang ZQ, Chang JW et al: Cultivation of urologic and male genital tumor cells. Zhonghua Zhong Liu Za Zhi, 1986; 8(3): 178-80
19. Davidson B, Elstrand MB, McMaster MT et al: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol, 2005; 96(1): 42
20. Ueda R, Shiku H, Pfreundschuh M et al: Cell surface antigens of human renal cancer defined by autologous typing, J Exp Med, 1979; 150: 564-679
21. Paul P, Rouas-Freiss N, Khalil-Daher I et al: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA, 1998; 95: 4510-15
22. Mickisch G, Fajta S, Keilhauer G et al: Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT). Urol Res, 1990; 18(2): 131-36
23. Kim FJ, Campagna A, Khandrika L et al: Individualized medicine for renal cell carcinoma: establishment of primary cell line culture from surgical specimens. J Endourol, 2008; 22: 2361-66
24. Arnould R, Dubois J, Abikhalil F et al: Comparison of two cytotoxicity assays - tetrazolium derivative reduction (MTT) and tritiated thymidine uptake - on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res, 1990; 10(1): 145-54
25. Ikemoto S, Sugimura K, Yoshida N et al: Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines. Urol Int, 2004; 73(4): 348-53
26. Okamoto M, Hara I, Miyake H et al: Synergistic antitumor effect of ionomycin and cisplatin against renal cell carcinoma in vitro and in vivo. Urology, 2001; 57(1): 188-92
27. Morais C, Pat B, Gobe G et al: Pyrrolidine dithiocarbamate exerts antiproliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant, 2006; 21(12): 3377-88
28. Ramp U, Mahotka C, Kalinski T et al: Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. Anticancer Res, 2001; 21(5): 3509-17
29. Domagk D, Bluthner-Hassler C, Kugler A et al: Influence of vinblastine on DNA parameters and multidrug resistance in renal cell carcinoma in vitro. Urol Res, 1998; 26(2): 123-27
30. Reinecke P, Corvin J, Gabbert HE, Gerharz CD: Antiproliferative effects of paclitaxel (Taxol) on human renal clear cell carcinomas in vitro. Eur J Cancer, 1997; 33(7): 1122-29